Skip to main content
TipRanks
Go Ultimate75% OFF

Carl Zeiss Meditec (0DHC) AI Stock Analysis

18 Followers
GB:0DHC

Carl Zeiss Meditec

(LSE:0DHC)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Diversified medical technology portfolioCarl Zeiss Meditec serves several important ophthalmic and microsurgical workflows rather than relying on a single device category. This breadth can support cross-selling, deepen customer relationships, and provide a more durable platform for growth as clinical needs and procedure volumes evolve.
Negative Factors
Recent revenue contractionThe reported revenue contraction indicates that recent demand or execution has not matched the company’s longer-term growth profile. If weakness persists, it could reduce operating leverage, slow expansion of the installed base, and limit the resources available for innovation and commercial investment.

Carl Zeiss Meditec (0DHC) vs. iShares MSCI United Kingdom ETF (EWC)

-50%-40%-30%-20%-10%0%10%20%30%GB:0DHC-13.10%EWC+21.04%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 3.13B
Dividend Yield
1.55%
Average Volume (3M)
29.40K
Price to Earnings (P/E)
21.0
Beta (1Y)
1.50
Revenue Growth
-0.06%
EPS Growth
-38.81%
Country
UK
Employees
5,784
Sector
General
Sector Strength
55
Industry
Medical - Instruments & Supplies

Carl Zeiss Meditec Business Overview & Revenue Model

Company Description

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis...

Carl Zeiss Meditec Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

GB:0DHC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DE:EUZDE:EUZ80OutperformEUR 959.88M17.6320.26%1.43%4.05%36.66%
DE:JENDE:JEN72OutperformEUR 2.07B20.759.74%1.11%4.05%37.55%
DE:DRW8DE:DRW870OutperformEUR 1.82B12.3910.20%2.61%5.06%40.18%
DE:SRTDE:SRT62NeutralEUR 17.83B71.367.81%0.32%4.19%63.32%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
DE:SBSDE:SBS54NeutralEUR 339.15M-7.99-18.69%2.15%――

* General Sector Average

Performance Comparison

0%50%100%GB:0DHCDE:DRW8DE:EUZDE:JENDE:SRTDE:SBSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0DHC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0DHCCarl Zeiss Meditec35.20-5.40-13.31%
DE:DRW8Draegerwerk AG & Co. KGaA (0MT8)84.8025.6643.40%
DE:EUZEckert & Ziegler Strahlen und Medizintechnik15.34-0.52-3.29%
DE:JENJenoptik AG36.1016.5884.95%
DE:SRTSartorius (0NIQ)225.5044.8824.85%
DE:SBSSTRATEC Biomedical27.907.9439.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.